ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of “Moderate Buy” from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $77.33.

Several research firms have recently issued reports on ANIP. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Piper Sandler began coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Truist Financial raised their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday. Finally, Raymond James increased their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock opened at $59.83 on Thursday. The business’s fifty day moving average is $58.51 and its 200 day moving average is $61.42. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -108.78 and a beta of 0.71. ANI Pharmaceuticals has a twelve month low of $48.20 and a twelve month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. During the same period last year, the business earned $1.05 EPS. ANI Pharmaceuticals’s quarterly revenue was up 12.5% compared to the same quarter last year. Research analysts expect that ANI Pharmaceuticals will post 3.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Texas Permanent School Fund Corp grew its position in ANI Pharmaceuticals by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock worth $912,000 after purchasing an additional 172 shares during the period. Louisiana State Employees Retirement System boosted its stake in shares of ANI Pharmaceuticals by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after buying an additional 200 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of ANI Pharmaceuticals by 4.7% in the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after acquiring an additional 211 shares during the period. Simplicity Wealth LLC increased its position in ANI Pharmaceuticals by 3.5% during the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 227 shares during the last quarter. Finally, California State Teachers Retirement System lifted its holdings in ANI Pharmaceuticals by 1.5% in the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 233 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.